X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to launch a local brand of the Covid-19 oral therapeutic treatment Paxlovid (nirmatrelvir/ritonavir) in an attempt to improve the access for treatment in China.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 29, 2023
Details:
Paliperidone Extended Release tablets is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
The agreement covers exclusive commercialization rights to CRB-701, a novel clinical stage antibody drug conjugate (ADC) targeting Nectin-4, in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: CRB-701
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Corbus Pharmaceuticals
Deal Size: $692.5 million Upfront Cash: $7.5 million
Deal Type: Licensing Agreement February 13, 2023
Details:
Harbour BioMed, HanAll’s licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab (HL161BKN), an FcRn compound originally discovered and developed by HanAll Biopharma.
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: HL161BKN
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Nona Biosciences
Deal Size: $138.6 million Upfront Cash: $20.8 million
Deal Type: Agreement October 11, 2022
Details:
Under the terms of the agreement, Elevation Oncology will develop and commercialize EO-3021 in all global territories outside of Greater China. EO-3021 (also known as SYSA1801) is a differentiated, clinical stage antibody drug conjugate that targets Claudin18.2.
Lead Product(s): SYSA1801
Therapeutic Area: Oncology Product Name: EO-3021
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Elevation Oncology
Deal Size: $1,175.0 million Upfront Cash: $27.0 million
Deal Type: Licensing Agreement July 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
